Company / Gross Profit
ENDONOVO THERAPEUTICS, INC. Gross Profit History
FY2014-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$125.4K
FY2022
5-year range
$58.1K / $216.8K
FY2018-FY2022
Trend
+115.7%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Profit returned to growth in FY2022 after 2 years of decline, reaching $125,365.
Based on SEC 10-K filings.
$125,365 in FY2022 with a 3-year CAGR of -16.7%.
Improved from $100,427 to $125,365 over the past 2 years.
Gross Profit over time
Growth rates
- 3-Year CAGR
- -16.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -16.7%, indicating a declining trend.
- In FY2022, gross profit increased 115.7% year-over-year.
- Peak gross profit was recorded in FY2019.
- Lowest gross profit in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -76.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $125.4K | +115.7% |
| FY2021 | $58.1K | -42.1% |
| FY2020 | $100.4K | -53.7% |
| FY2019 | $216.8K | +208.2% |
| FY2018 | $70.3K | - |
| FY2016 | - | - |
| FY2015 | $2.1K | -75.8% |
| FY2014 | $8.7K | - |
| FY2011 | - | - |
As of FY2022 · SEC 10-K · Updated Jun 29, 2026